Abstract
Vascular endothelial growth factor-A165 (VEGF-A165) is the key mediator of angiogenesis which has been explored as a therapeutic agent to control angiogenesis and revascularisation of ischaemic tissues. Unfortunately, the use of VEGF-A165 has failed to improve angiogenic outcomes in clinical trials, despite showing promising results in vitro and in vivo. We propose that these failures occurred due to therapies using VEGF-A165 lacking appropriate glycosylation.
The aim of this project was to test the angiogenic capacity of differentially glycosylated isoforms (glycoforms) of VEGF-A165.